美国Ｓｙｎａｐｔｉｃ制药公司发现一种新的、强效的以治疗抑郁为靶标的药物 ,此药物的作用靶点为一种Ｇ蛋白偶联受体 (ＧＰＣＲ)。Ｓｙｎａｐｔｉｃ制药公司还验证了其他几个候选药物 ,并在动物实验中证明它们作用于ＧＰＣＲ产生抗抑郁作用。进一步的临床前研究正在进行 ,公司 Synaptic Pharmaceuticals of the United States has discovered a new, potent drug for the treatment of depression, which targets a G protein-coupled receptor (GPCR). Synaptic Pharmaceuticals also validated several other drug candidates and demonstrated in animal experiments that they exert antidepressant effects on GPCRs. Further preclinical studies are underway at the company